Retatrutide: Triple Receptor Agonism and Glucagon Pathway Research
Last updated 2026-10-21
Retatrutide adds glucagon receptor agonism to the incretin pairing found in tirzepatide. That third receptor is the entire scientific interest of the molecule. It remains investigational and unapproved.
Why add glucagon receptor agonism
Glucagon receptor agonism is mechanistically counterintuitive in a metabolic context, since glucagon raises blood glucose. The research rationale is that hepatic glucagon receptor activation increases energy expenditure and drives hepatic lipid oxidation — pathways not engaged by incretin agonism alone.
The design premise is that concurrent GLP-1 receptor agonism offsets the glycemic effect of glucagon receptor activation, permitting the energy expenditure and hepatic lipid handling effects to be studied without the glucose excursion.
This makes retatrutide a genuinely useful tool compound for dissecting the contribution of each receptor arm, independent of any downstream application.
Evidence status and regulatory position
Retatrutide is investigational. Eli Lilly's Phase 3 TRIUMPH program reported between December 2025 and July 2026, and the first full report appeared in the New England Journal of Medicine in September 2026. Lilly has said it intends to seek approval.
It is not approved by the FDA or any other regulator for any use, and the FDA has stated that retatrutide sold online is an unapproved drug. Clinical-trial material is manufactured and released under an investigational new drug application; research-grade material is a laboratory chemical with a different supply chain and different paperwork. Trial findings describe Lilly's material in Lilly's trials and say nothing about any research-grade supply.
For laboratory work the practical consequence is a much larger published reference base for receptor-pharmacology comparisons than existed a year ago, and the same requirement as before: the certificate for the specific lot is the only evidence about the material in the vial.
Laboratory handling
Store lyophilized at -20°C protected from light; reconstituted at 2-8°C for approximately 30 days.
Reconstitute with bacteriostatic water directed down the vial wall. Swirl gently until fully dissolved; do not shake.
Evidence assessment
Evidence base: substantial and recent. Receptor pharmacology characterized (Coskun 2022); Phase 3 program reported 2025-2026; investigational and unapproved.
Published literature
161 papers indexed on PubMed for Retatrutide. Showing 12, reviews first.
- 01Retatrutide-A Game Changer in Obesity Pharmacotherapy
Katsi V et al. · Biomolecules · 2025
- 02What is the pipeline for future medications for obesity?
Melson E et al. · Int J Obes (Lond) · 2025
- 03Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker DJ · Diabetes Care · 2024
- 04Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Locatelli JC et al. · Diabetes Care · 2024
- 05Gut hormones and appetite regulation
Hong SH, Choi KM · Curr Opin Endocrinol Diabetes Obes · 2024
- 06
- 07Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis M et al. · Pharmacol Rev · 2025
- 08
- 09Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression
Marathe SJ et al. · NPJ Metab Health Dis · 2025
- 10Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff AM et al. · N Engl J Med · 2023
- 11
- 12
Indexed from PubMed on 2026-07-19. Citations link to the source; we do not reproduce abstracts.
All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.